Business
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s CDE in March 2026 Completed acquisition of Cullgen in an approximately $300 million all-stock transaction, expanding pipeline into inflammatory diseases and cancers First patient enrolled in Phase 2/3 trial evaluating ETUARY™ for radiation-induced lung injury, including immune-related pneum
About this update from Gyre Therapeutics, Inc.
[{"type":"image","alt":"Gyre Therapeutics Inc.","displaySize":"","headline":null,"caption":"Gyre Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/c821ee8b66ffe1346b42dcf8cb4fcc33"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZZ7gx8fH_Oooli7z1WaHxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/c821ee8b66ffe1346b42dcf8cb4fcc33","width":300,"height":63},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZZ7gx8fH_Oooli7z1WaHxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/c821ee8b66ffe1346b42dcf8cb4fcc33","width":300,"height":63}},"lazy":false},{"type":"text","content":"Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10)","length":57,"tagName":"p"},{"type":"text","content":"Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed","length":68,"tagName":"p"},{"type":"text","content":"NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s CDE in March 2026","length":99,"tagName":"p"},{"type":"text","content":"Completed acquisition of Cullgen in an approximately $300 million all-stock transaction, expanding pipeline into inflammatory diseases and cancers","length":146,"tagName":"p"},{"type":"text","content":"First patient enrolled in Phase 2/3 trial evaluating ETUARY™ for radiation-induced lung injury, including immune-related pneumonitis","length":132,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, the Company or Gyre Therapeutics) (Nasdaq: GYRE), an innovative, commercial stage biopharmaceutical company with operations in the United States and China, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.","length":340,"tagName":"p"},{"type":"text","content":"“Building on our successful pre-NDA meeting with China’s CDE at the beginning of the year, we are particularly encouraged by the NMPA’s priority review designation for F351, reinforcing both the strength of our clinical data and the significant unmet need in liver fibrosis,” said Ying Luo, Chief Executive Officer of Gyre Therapeutics. “In parallel, our acquisition of Cullgen expands our capabilities into targeted protein degradation, positioning Gyr...